The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system

Introduction

Each year, over 250 babies are born without a thymus. These babies have a life expectancy of 2-3 years. The only cure is transplantation of thymus tissue, but this has a 30% mortality rate and costs almost €2.5M.

Project Overview

We developed i-Thymus, a revolutionary cure based on the patient’s own cells, leveraging innovative gene therapy to generate thymus organoids that can be implanted minimally invasively in the patient (Fig. 1).

Proof of Concept

We have already shown this works in a functional proof of concept in vivo.

Future Plans

With this EIC Accelerator, we will finalize development to enter the clinic for a Phase I/II trial, aiming to enter the EU market with a pharma partner by 2028.

Market Strategy

After rapid market entry with ODD for complete DiGeorge syndrome, we will leverage this clinical success and our first revenues to develop i-Thymus for unmet needs of hundreds of thousands of other patients.

Target Patient Population

We will start with AML patients who have lost thymus function after high-dose chemotherapy for stem cell transplantation.